Recommended optimal range for the count of examined lymph nodes and lymph node ratio for postoperative adjuvant radiotherapy in patients with pN2 non-small cell lung cancer: a multicenter retrospective cohort investigation.
{"title":"Recommended optimal range for the count of examined lymph nodes and lymph node ratio for postoperative adjuvant radiotherapy in patients with pN2 non-small cell lung cancer: a multicenter retrospective cohort investigation.","authors":"Qiming Huang, Xiang Weng, Yiliang Hu, Zhenjie Li, Longren Wu, Zijian Hu, Dongliang Yu, Linmin Xiong","doi":"10.21037/jtd-24-1573","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent evidence suggests that postoperative adjuvant radiotherapy (PORT) may enhance survival outcomes in patients with pN2 non-small cell lung cancer (NSCLC), particularly when evaluating through examined lymph nodes (ELNs) and lymph node ratio (LNR). This study aims to explore the impact of ELNs and LNR on the efficacy of postoperative radiotherapy in pN2 stage NSCLC patients through a multicenter retrospective cohort analysis, providing valuable insights for clinical treatment decisions.</p><p><strong>Methods: </strong>Data were meticulously extracted from the Surveillance, Epidemiology, and End Results (SEER) 17 registry spanning 2015 to 2019. The study specifically targeted pN2 stage NSCLC patients who underwent surgical intervention and lymph node biopsy, involving an analysis of 1,875 patients while excluding those with incomplete data. The impact of PORT on overall survival (OS) was assessed, stratified by ELNs and LNR. Statistical analyses employed X-tile software to categorize LNR into three distinct groups, and Cox proportional hazard models were utilized to evaluate the influence of various factors on OS.</p><p><strong>Results: </strong>The Cox proportional hazards model revealed a significant survival advantage associated with PORT, demonstrating a 22% higher mortality rate in the non-PORT group [hazard ratio (HR) =1.22, 95% confidence interval (CI): 1.02-1.46, P=0.03] and up to 31% higher in the fully adjusted model (HR =1.31, 95% CI: 1.09-1.58, P=0.004). PORT notably improved survival in patients with ELNs <10, particularly when LNR ≤0.2 (HR =4.15, P=0.03) and LNR ≥0.53 (HR =1.83, P=0.01). Kaplan-Meier survival curves corroborated these findings.</p><p><strong>Conclusions: </strong>Our findings indicate that the number of ELNs and the LNR could serve as valuable criteria for selecting pN2 NSCLC patients who may benefit from PORT. PORT has been linked to improved survival outcomes in pN2 stage NSCLC, with a particular emphasis on its efficacy in patients with ELNs <10 and an LNR of ≤0.2.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"17 2","pages":"784-795"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898341/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of thoracic disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/jtd-24-1573","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Recent evidence suggests that postoperative adjuvant radiotherapy (PORT) may enhance survival outcomes in patients with pN2 non-small cell lung cancer (NSCLC), particularly when evaluating through examined lymph nodes (ELNs) and lymph node ratio (LNR). This study aims to explore the impact of ELNs and LNR on the efficacy of postoperative radiotherapy in pN2 stage NSCLC patients through a multicenter retrospective cohort analysis, providing valuable insights for clinical treatment decisions.
Methods: Data were meticulously extracted from the Surveillance, Epidemiology, and End Results (SEER) 17 registry spanning 2015 to 2019. The study specifically targeted pN2 stage NSCLC patients who underwent surgical intervention and lymph node biopsy, involving an analysis of 1,875 patients while excluding those with incomplete data. The impact of PORT on overall survival (OS) was assessed, stratified by ELNs and LNR. Statistical analyses employed X-tile software to categorize LNR into three distinct groups, and Cox proportional hazard models were utilized to evaluate the influence of various factors on OS.
Results: The Cox proportional hazards model revealed a significant survival advantage associated with PORT, demonstrating a 22% higher mortality rate in the non-PORT group [hazard ratio (HR) =1.22, 95% confidence interval (CI): 1.02-1.46, P=0.03] and up to 31% higher in the fully adjusted model (HR =1.31, 95% CI: 1.09-1.58, P=0.004). PORT notably improved survival in patients with ELNs <10, particularly when LNR ≤0.2 (HR =4.15, P=0.03) and LNR ≥0.53 (HR =1.83, P=0.01). Kaplan-Meier survival curves corroborated these findings.
Conclusions: Our findings indicate that the number of ELNs and the LNR could serve as valuable criteria for selecting pN2 NSCLC patients who may benefit from PORT. PORT has been linked to improved survival outcomes in pN2 stage NSCLC, with a particular emphasis on its efficacy in patients with ELNs <10 and an LNR of ≤0.2.
期刊介绍：
The Journal of Thoracic Disease (JTD, J Thorac Dis, pISSN: 2072-1439; eISSN: 2077-6624) was founded in Dec 2009, and indexed in PubMed in Dec 2011 and Science Citation Index SCI in Feb 2013. It is published quarterly (Dec 2009- Dec 2011), bimonthly (Jan 2012 - Dec 2013), monthly (Jan. 2014-) and openly distributed worldwide. JTD received its impact factor of 2.365 for the year 2016. JTD publishes manuscripts that describe new findings and provide current, practical information on the diagnosis and treatment of conditions related to thoracic disease. All the submission and reviewing are conducted electronically so that rapid review is assured.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
